A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Crenigacestat (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Eli Lilly
- 15 Sep 2017 Planned End Date changed from 1 May 2020 to 1 Jun 2018.
- 15 Sep 2017 Planned primary completion date changed from 1 May 2019 to 1 Dec 2017.
- 12 Sep 2017 Results ( n=63) presented at the 42nd European Society for Medical Oncology Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History